Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers, dialysis machines, hemodialysis machines, A.V. fistula needle sets, extracorporeal blood circuits, bloodlines, and plasma separators; peritoneal dialysis (PD) solutions; and PD consumables, such as bag free set, c… Read more
Shandong Weigao Blood (603014) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.32 Billion CNY
Based on the latest financial reports, Shandong Weigao Blood (603014) has total liabilities worth CN¥1.32 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shandong Weigao Blood - Total Liabilities Trend (2021–2024)
This chart illustrates how Shandong Weigao Blood's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shandong Weigao Blood Competitors by Total Liabilities
The table below lists competitors of Shandong Weigao Blood ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Israel China Biotechnology (ICB) Ltd
TA:ICB
|
Israel | ILA4.11 Million |
|
Hollywood Bowl Group PLC
LSE:BOWL
|
UK | GBX287.93 Million |
|
Rank Group PLC
LSE:RNK
|
UK | GBX440.00 Million |
|
Veteranpoolen AB Series B
ST:VPAB-B
|
Sweden | Skr91.03 Million |
|
Sporttotal AG
F:WIG1
|
Germany | €50.80 Million |
|
SUNOPTA - Dusseldorf Stock Exchang
DU:ZSK
|
Germany | €538.07 Million |
|
M'BISHI CHEM HLDGS
MU:M3C
|
Germany | €3.83 Trillion |
Liability Composition Analysis (2021–2024)
This chart breaks down Shandong Weigao Blood's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Weigao Blood's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Weigao Blood (2021–2024)
The table below shows the annual total liabilities of Shandong Weigao Blood from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.39 Billion | -9.84% |
| 2023-12-31 | CN¥1.55 Billion | -11.33% |
| 2022-12-31 | CN¥1.74 Billion | -23.01% |
| 2021-12-31 | CN¥2.26 Billion | -- |